Skip to main navigation Skip to search Skip to main content

Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A

Charlotte Katharina Brierley*, Bon Ham Yip, Giulia Orlando, Jeremy Wen, Sean Wen, Harsh Goyal, Max Levine, G. Maria Jakobsdottir, Avraam Tapinos, Alex J. Cornish, Antonio Rodriguez-Romera, Alba Rodriguez-Meira, Matthew Bashton, Angela Hamblin, Sally Ann Clark, Joseph C. Hamley, Olivia Fox, Madalina Giurgiu, Jennifer O’Sullivan, Lauren MurphyAssunta Adamo, Aude Anais Olijnik, Anitria Cotton, Emily Hendrix, Shilpa Narina, Shondra M. Pruett-Miller, Amir Enshaei, Claire Harrison, Mark Drummond, Steven Knapper, Ayalew Tefferi, Iléana Antony-Debré, James Davies, Anton G. Henssen, Supat Thongjuea, David C. Wedge, Stefan N. Constantinescu, Elli Papaemmanuil, Bethan Psaila, John D. Crispino*, Adam J. Mead*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    8 Citations (Scopus)
    25 Downloads (Pure)

    Abstract

    Chromothripsis, the chaotic shattering and repair of chromosomes,
    is common in cancer. Whether chromothripsis generates actionable
    therapeutic targets remains an open question. In a cohort of 64 patients
    in blast phase of a myeloproliferative neoplasm (BP-MPN), we describe
    recurrent amplification of a region of chromosome 21q (‘chr. 21amp’) in 25%,
    driven by chromothripsis in a third of these cases. We report that chr. 21amp
    BP-MPN has a particularly aggressive and treatment-resistant phenotype.
    DYRK1A, a serine threonine kinase, is the only gene in the 2.7-megabase
    minimally amplified region that showed both increased expression and
    chromatin accessibility compared with non-chr. 21amp BP-MPN controls.
    DYRK1A is a central node at the nexus of multiple cellular functions critical
    for BP-MPN development and is essential for BP-MPN cell proliferation
    in vitro and in vivo, and represents a druggable axis. Collectively, these
    findings define chr. 21amp as a prognostic biomarker in BP-MPN, and link
    chromothripsis to a therapeutic target.
    Original languageEnglish
    Pages (from-to)1478-1492
    Number of pages15
    JournalNature Genetics
    Volume57
    Issue number6
    Early online date9 Jun 2025
    DOIs
    Publication statusPublished - Jun 2025

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A'. Together they form a unique fingerprint.

    Cite this